Saxenda vs Wegovy for weight loss: which one is right for you?

How the two medicines compare on paper, and where the comparison gets complicated

Liraglutide (Saxenda) and semaglutide (Wegovy) both slow gastric emptying, reduce appetite and act on GLP-1 receptors, so they share a pharmacological family. The differences sit in potency, frequency and the volume of evidence behind them. The STEP 1 trial, published in the New England Journal of Medicine, found that adults taking semaglutide 2.4mg once weekly lost an average of around 15% of body weight over 68 weeks alongside lifestyle support, compared with around 2.4% in the placebo group. Saxenda's pivotal trial data, at its 3mg daily dose, showed average losses closer to 5–8% depending on the study population and duration.

The table below sets out the key factual differences. Note that head-to-head randomised trials between these two medicines are limited; if you want to understand whether Wegovy is better than Saxenda, comparisons across separate trials should be read with caution.

The full semaglutide vs Saxenda comparison explores the pharmacology in more depth if you want the mechanism-level detail.

The daily versus weekly injection: a smaller practical gap than you might think, or a bigger one

For some people this is the decision. Saxenda's titration schedule means injecting every day from week one, climbing from 0.6mg toward 3mg over five weeks. Wegovy starts at 0.25mg weekly and titrates roughly every four weeks. If you travel frequently, work shifts or simply forget medicines taken daily, the once-weekly pen removes one source of friction. Some patients find the opposite: a daily routine embeds more easily than a specific weekly day they have to remember.

Worth thinking about: if you tend to order prescriptions around payday or leave things until a Monday, a once-weekly injection has a narrower penalty for a slightly late dose than a daily one, though your prescriber and the patient leaflet have the definitive guidance on what to do if a dose is missed.

The injection technique itself is similar for both medicines: a subcutaneous injection into the abdomen, thigh or upper arm. Wegovy's pre-filled pen is designed for once-weekly use; Saxenda uses a daily dial-a-dose pen. Neither requires mixing or specialist training, but confidence with the device matters. Our prescribers hear fairly often that the anticipation of injecting is worse than the reality.

Eligibility in the UK: where the two medicines align and where they diverge

Both medicines are licensed for adults with a BMI of 30 or above, or 27 and above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. The licensed starting point is similar. The divergence comes at the NICE layer. NICE's appraisal of semaglutide (TA875) recommends Wegovy within specialist weight management services, subject to specific criteria including BMI thresholds and a maximum treatment duration of two years. No equivalent NICE technology appraisal exists for Saxenda, which means NHS access routes are different and, in practice, patchier.

On the private side, a prescriber considers the whole clinical picture: your BMI, any comorbidities, your medication history and whether there are any contraindications. The eligibility criteria for Wegovy are explored in more detail in our dedicated guide. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance; that adjustment is factored into a clinical assessment rather than being something you self-determine.

Pregnancy, breastfeeding and actively trying to conceive are contraindications for both medicines, and neither is licensed for under-18s. Anyone with a history of medullary thyroid carcinoma or MEN2 should discuss this with their prescriber before starting either treatment. The NHS medicines page for semaglutide sets out the full list of conditions and interactions to discuss.

What Saxenda not being available from our pharmacy actually means for you

Our GPhC-registered pharmacy (registration number 9012878, verifiable on the GPhC register) dispenses Wegovy for weight management and Mounjaro (tirzepatide), the dual GIP and GLP-1 receptor agonist that produced average weight losses of around 20–21% at its highest dose in the SURMOUNT-1 trial. We do not dispense Saxenda. This is not a clinical judgment about liraglutide; it is simply a dispensing decision, and it means this page is educational rather than an access route for that medicine.

If you have been on Saxenda and are wondering whether switching makes sense, our guide covering whether Wegovy is better than Saxenda for weight loss can help you think through the evidence before speaking to a prescriber. For anyone exploring weight-loss treatment options more broadly, the landscape in the UK currently centres on Wegovy and Mounjaro as the two licensed injectable options for weight management, with an oral semaglutide tablet (Wegovy tablets) now also MHRA-approved. That is where clinical conversations tend to land in 2025 and 2026.

Which of these is better for you specifically is a clinical decision, made with a prescriber who has reviewed your full picture. The comparison above gives you the evidence; the consultation gives you the answer. Check your eligibility with our team if you are ready to take that step.